No connection

Search Results

SONM

BEARISH
$3.0 Live
DNA X, Inc. · NASDAQ
$2.52 52W Range $38.52
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 20, 2026
Market cap
$4.47M
P/E
N/A
ROE
N/A
Profit margin
N/A
Debt/Equity
N/A
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
The company exhibits extreme financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental health. With a Quick Ratio of 0.03 and a negative Price-to-Book ratio of -4.35, the firm is facing a severe liquidity crisis and possesses negative shareholders' equity. Catastrophic Q/Q revenue growth of -394.48% and a 5-year price decline of 99.7% suggest a business in terminal decline. The lack of an Altman Z-Score calculation is likely due to the absence of positive working capital or equity, further signaling insolvency risk.

Key Strengths

Recent reduction in quarterly EPS loss ($-9.36 vs $-25.38)
Low current price relative to 52-week high
Positive YoY EPS growth (though starting from a deep negative base)
Low PEG ratio (mathematically low, though fundamentally unreliable)
Recent 1-week price stabilization

Key Risks

Imminent insolvency risk due to Quick Ratio of 0.03
Negative shareholders' equity (Price/Book -4.35)
Catastrophic collapse in quarterly revenue (-394.48%)
Consistent history of missing earnings estimates
Extreme price volatility and long-term value destruction (-99.7% over 5 years)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
2
Weak
Value
0
Future
10
Past
0
Health
0
Dividend
0
AI Verdict
High Risk of Insolvency
Key drivers: Piotroski F-Score 0/9, Negative Equity, Severe Liquidity Shortage, Revenue Collapse
Confidence
95%
Value
0/100

P/B of -4.35 indicates the company's liabilities far exceed its assets.

Positives
No standout positives identified.
Watchpoints
  • Negative Price/Book ratio
  • No Graham Number available due to negative earnings/equity
Future
10/100

Growth metrics are catastrophic; EPS 'growth' is merely a reduction in losses.

Positives
  • Recent EPS improvement
Watchpoints
  • Q/Q Revenue growth of -394.48%
  • Lack of analyst coverage
Past
0/100

Long-term price performance indicates a total loss of investor confidence.

Positives
No standout positives identified.
Watchpoints
  • 5Y Change: -99.7%
  • 1Y Change: -89.8%
  • Consistent earnings misses
Health
0/100

The company cannot meet short-term obligations with liquid assets.

Positives
No standout positives identified.
Watchpoints
  • Piotroski F-Score 0/9
  • Quick Ratio 0.03
  • Current Ratio 0.60
Dividend
0/100

Company is in no position to return capital to shareholders.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 Dividend Strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$3.0

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for SONM and closest competitors.

Updated 2026-04-17
SON
DNA X, Inc.
Primary
5Y
-99.7%
3Y
-98.6%
1Y
-89.8%
6M
-79.4%
1M
-20.0%
1W
+1.0%
HTC
HeartCore Enterprises, Inc.
Peer
5Y
-95.8%
3Y
-76.1%
1Y
-68.3%
6M
-75.8%
1M
-32.5%
1W
0.0%
AST
Astrotech Corporation
Peer
5Y
-96.0%
3Y
-78.3%
1Y
-56.3%
6M
-45.4%
1M
-20.4%
1W
+0.4%
IZM
ICZOOM Group Inc.
Peer
5Y
-87.2%
3Y
-77.6%
1Y
-75.2%
6M
-81.8%
1M
-25.4%
1W
-26.7%
JTA
Jet.AI Inc.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-99.3%
6M
-98.9%
1M
-68.8%
1W
-62.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
3.57
PEG Ratio
0.25
P/B Ratio
-4.35
P/S Ratio
N/A
EV/Revenue
N/A
EV/EBITDA
-3.97
Market Cap
$4.47M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin N/A
Gross Margin N/A
ROE N/A
ROA -8.08%

Growth

Revenue and earnings growth rates

Revenue Growth N/A
Earnings Growth N/A
Q/Q Revenue Growth -394.48%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
N/A
Current Ratio
0.6
Weak
Quick Ratio
0.03
Poor
Cash/Share
$0.88

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$-0.0B
Gross Margin
25.0%
Op. Margin
-10.6%
Net Margin
20.1%
Total Assets
$0.0B
Liabilities
$0.1B
Equity
$-0.0B
Debt/Equity
-7.53x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2024-11-13
$-9.36
+21.2% surprise
2024-08-09
$-25.38
-161.1% surprise
2024-05-14
$-12.6
-133.3% surprise
2024-03-27
$-5.4
-400.0% surprise

Technology Sector Comparison

Comparing SONM against 465 companies in the Technology sector (38 bullish, 160 neutral, 267 bearish)
Current Ratio
0.6
This Stock
vs
3.85
Sector Avg
-84.3% (Weaker)

Similar Companies

Peer comparison within the same industry

SONM DNA X, Inc.
BEARISH
Mkt Cap
$4M
P/E
-
ROE
-%
Price
$3.0
HTCR HeartCore...
BEARISH
Mkt Cap
$4M
P/E
-
ROE
-77.9%
Price
$3.4
 Compare with SONM
ASTC Astrotech Corporation
BEARISH
Mkt Cap
$5M
P/E
-
ROE
-64.0%
Price
$2.81
 Compare with SONM
IZM ICZOOM Group Inc.
BEARISH
Mkt Cap
$5M
P/E
4.2
ROE
7.8%
Price
$0.42
 Compare with SONM
JTAI Jet.AI Inc.
BEARISH
Mkt Cap
$4M
P/E
0.1
ROE
32.2%
Price
$6.06
 Compare with SONM

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

CROLIUS CLAYTON
Chief Financial Officer
Stock Award
2026-02-09
35,000 shares
MULICA MICHAEL C
Chief Executive Officer
Stock Award
2026-02-09
50,000 shares
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-04-15

Sonoma Pharmaceuticals, Inc. filed an 8-K on April 15, 2026, likely to report its first-quarter financial results.

10-K
10-K
2026-04-15

SONM filed its annual 10-K report on April 15, 2026. The provided excerpts do not contain specific financial highlights or detailed risk factors.

8-K/A
8-K/A
2026-03-02

SONM filed an amendment to a previously submitted Form 8-K on March 2, 2026.

8-K
8-K
2026-02-10

Sonoma Pharmaceuticals, Inc. filed an 8-K on February 10, 2026, likely to announce its annual financial results or a material corporate update.

8-K
8-K
2026-02-05

Sonoma Pharmaceuticals filed an 8-K on February 5, 2026, likely to report its fourth quarter and full-year financial results.

8-K
8-K
2026-01-27

Sonoma Pharmaceuticals, Inc. filed a current report on January 27, 2026, likely announcing its fourth-quarter and full-year financial results.

8-K
8-K
2025-12-31

Sonoma Pharmaceuticals, Inc. filed a current report on December 31, 2025, likely reporting year-end financial results or a material corporate event coinciding with the close of the fiscal year.

8-K
8-K
2025-12-18
8-K
8-K
2025-12-05
8-K
8-K
2025-11-26
8-K
8-K
2025-11-13
8-K
8-K
2025-10-31
10-Q
10-Q
2025-10-31
8-K
8-K
2025-10-24
8-K
8-K
2025-10-20
Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning SONM from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile